The definition
A peptide is a chain of amino acids joined by peptide bonds — amide linkages formed between the carboxyl group of one amino acid and the amino group of the next, releasing a molecule of water at each junction.
That is the whole definition. Everything else is a question of length, sequence, and what the chain does once it folds.
By convention, chains of roughly two to fifty amino acids are called peptides, and anything longer is called a protein. The boundary is a naming convention rather than a physical transition — nothing changes about the chemistry at residue fifty-one. Sub-categories follow the same loose logic: dipeptides and tripeptides have two and three residues, oligopeptides run to about twenty, and polypeptides extend beyond that.
Insulin sits almost exactly on the line. At 51 amino acids across two disulfide-linked chains, it is described as a peptide hormone in some texts and a small protein in others. Both are correct, which tells you how much weight the distinction can bear.
Peptides are ordinary biology
Peptides are not an exotic class of compound. They are one of the body's standard signalling formats, and several of the best-characterised molecules in human physiology are peptides:
| Peptide | Length | Role in normal physiology |
|---|---|---|
| Oxytocin | 9 residues | Uterine contraction, milk ejection |
| Vasopressin | 9 residues | Water retention, vascular tone |
| Glucagon | 29 residues | Raises blood glucose |
| GLP-1 | 30 residues | Incretin signalling after a meal |
| Insulin | 51 residues (2 chains) | Glucose uptake |
These are endogenous molecules. They are listed here to make a structural point — that the peptide format is a common one in mammalian signalling — not to suggest anything about the research compounds discussed elsewhere on this site.
Why the format is scientifically interesting
Peptides occupy a middle ground between small-molecule drugs and full proteins, and the trade-offs are well characterised in the pharmacology literature.
Selectivity. A peptide presents a large, shaped binding surface, so it can engage a specific receptor with high selectivity. Small molecules, being smaller, more often bind several related targets.
Poor oral bioavailability. The digestive tract exists to hydrolyse amide bonds. A peptide taken orally is largely degraded to constituent amino acids before absorption, which is why peptide pharmaceuticals are overwhelmingly parenteral, and why oral peptide formulation is an active and difficult area of research.
Short half-life. Circulating peptidases clear most peptides quickly. Much of the medicinal chemistry in this field is devoted to slowing that clearance.
None of these properties is a benefit or a drawback in the abstract. They are constraints that determine what a given sequence can and cannot be studied for.
How peptides are manufactured
Nearly all synthetic peptides are produced by solid-phase peptide synthesis (SPPS), the method Bruce Merrifield introduced in 1963 and received the Nobel Prize in Chemistry for in 1984.
The growing chain is anchored to an insoluble resin bead. Amino acids are added one at a time, each cycle consisting of deprotection, coupling, and washing. Because the product stays bound to the resin, excess reagent is simply rinsed away between steps. The two dominant chemistries are Fmoc and Boc, named for the protecting group used on the incoming residue.
This is where purity comes from, and where it is lost. Each coupling step is efficient but not perfect. If every step proceeds at 99% yield, a 30-residue peptide requires 29 couplings, and the theoretical maximum yield of the correct full-length sequence is 0.99²⁹ — about 75%. At 98% per step it falls to roughly 56%.
The remainder is not empty space. It is a population of closely related impurities:
- Deletion sequences — a residue was skipped
- Truncated sequences — the chain terminated early
- Diastereomers — a residue racemised during coupling
- Incompletely deprotected species — a side-chain protecting group survived cleavage
These impurities resemble the target closely, which is precisely what makes them difficult to separate and important to measure.
What the analytical methods actually tell you
Two techniques do most of the work on a certificate of analysis, and they answer different questions.
HPLC answers "how much of this is one thing?" Reversed-phase high-performance liquid chromatography separates components by hydrophobicity. Purity is reported as the area of the main peak relative to total peak area — a relative measure. A 99% figure means the main peak accounts for 99% of what the detector saw at the chosen wavelength. It does not confirm that the main peak is the intended molecule, and it says nothing about material the detector cannot see.
Mass spectrometry answers "is this the right thing?" MS measures mass-to-charge ratio, confirming the observed mass matches the sequence's theoretical mass. It establishes identity but is not a quantitative purity measure.
Neither is sufficient alone. A certificate showing high HPLC purity without mass confirmation demonstrates that a sample is homogeneous, not that it is what the label says. A mass spectrum without a chromatogram demonstrates the target is present, not that little else is.
Why peptides are supplied lyophilized
Water is the main driver of peptide degradation, and the mechanisms are well documented:
- Hydrolysis of the peptide backbone, cleaving the chain
- Oxidation of methionine, cysteine and tryptophan side chains
- Deamidation of asparagine and glutamine
- Aggregation, in which chains associate irreversibly
Lyophilization — freeze-drying — removes water and slows all of these. It is a stability measure, which is also why storage temperature and moisture exclusion are specified for research material, and why a certificate describes the material as it was at the time of assay rather than indefinitely.
What is not established
Most compounds referred to as "research peptides" have limited or no published human clinical data. A substantial share of the available literature is preclinical: cell culture, or rodent models, often at doses and routes that do not translate directly to other species.
Preclinical findings are a reason to investigate a question further. They are not evidence of a clinical effect, and the gap between the two is where most of the field's uncertainty sits.
Regulatory status follows from this. Most such compounds are not approved by the FDA for any indication and are supplied for research use only — not for human or veterinary use.
Further reading on this site
For research use only · Not for human or veterinary use · No compound discussed here is FDA-approved for any indication